Related Experiment Video
Updated: Jun 17, 2026
10:16
Generating Genetically Modified Plasmodium berghei Sporozoites
Published on: May 5, 2023
Development of the RTS,S/AS malaria candidate vaccine
Johan Vekemans1, Amanda Leach, Joe Cohen
1GlaxoSmithKline Biologicals, 89 rue de l'Institut, 1330 Rixensart, Belgium. johan.vekemans@gskbio.com
Vaccine
|December 17, 2009
Summary
A new malaria vaccine targeting the circumsporozoite protein shows promise. Ongoing trials in African children are assessing its safety and efficacy for public health benefits.
Area of Science:
- Immunology
- Vaccinology
- Tropical Medicine
Background:
- Malaria remains a significant global health challenge, necessitating novel control strategies.
- Existing malaria control tools require complementary interventions, such as effective vaccines.
- The RTS,S/AS vaccine candidate, targeting the circumsporozoite protein, represents a leading advancement.
Purpose of the Study:
- To evaluate the safety, immunogenicity, and efficacy of the RTS,S/AS malaria vaccine candidate.
- To assess the potential public health benefits of the RTS,S/AS vaccine.
- To gather regulatory data for potential vaccine licensing.
Main Methods:
- Clinical trials involving children and infants in malaria-endemic regions of Africa.
- Investigation of immune responses (immunogenicity) to the vaccine.
- Assessment of the vaccine's effectiveness in preventing malaria (efficacy).
Main Results:
- The RTS,S/AS vaccine candidate has demonstrated promising safety and immunogenicity profiles.
- Preliminary efficacy data suggests potential public health benefits.
- A large-scale, multicenter Phase III trial has been initiated.
Conclusions:
- The RTS,S/AS vaccine is a promising candidate to complement existing malaria control measures.
- Further characterization of efficacy in a Phase III trial is crucial for regulatory approval.
- Successful licensing could provide significant public health benefits in malaria-endemic areas.
Related Concept Videos
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
00:58Symbiosis
Symbiotic relationships are long-term, close interactions between individuals of different species that affect the distribution and abundance of those species. When a relationship is beneficial to both species, this is called mutualism. When the relationship is beneficial to one species but neither beneficial nor harmful to the other species, this is called commensalism. When one organism is harmed to benefit another, the relationship is known as parasitism. These types of relationships often...
01:26Rocky Mountain Spotted Fever
Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...